| auxilium |
|
|
1 2 3 4
|
| 1 2 3 4
|
|
06/26/2006 23:43
Randy H. not registered
|
06/26/2006 23:43
Randy H. not registered
|
French Fries
jim,
So you think that just the *promise* of eventual Collagenase would be enough to keep CHS doing OS when they know very well that NA is both safe and effective and approved by their leading society, the ASSH?
Keep in mind that Eaton has indeed snatched the pebble from hands of the French. He's refined the procedure, even now calls it the "Eaton method". Essentially, it's no longer French. He has successfully Americanized and CHS it. I assume American hand surgeons eat French Fries? They aren't really French either :-)
Actually NA is a just a modified form of percutaneous fasciotomy which is one of the *original* surgical treatments for Dups. The difference now is that only a needle is used and the right kind of numbing agent uses patient feedback to avoid nerve injury. Otherwise percutaneous fasciotomy isn't strange to CHS in the least. It's just out of fashion. However, these new twists by Lermusiaux make it a very safe effective piece of cake. But you know all that.
If there were just one CHS in each metro area who offered NA, say maybe 50 CHS or so, word of mouth plus 20 more websites touting the benefits of NA would chip away at the OS juggernaut faster and faster.
It's funny how I'm just more optimistic that both non-invasive treatments can and will move forward quickly, while it would seem that you feel that in Five years neither will have made much of a dent. I agree 1% NA is not a dent. 20% is a dent. Eaton thinks he can do it. Lets watch.
|
|
|
|
|
06/29/2006 23:31
Rednot registered
|
06/29/2006 23:31
Rednot registered
|
Collegenase
"Fickenscher said the board was looking for someone with "the right commercial presence" and experience to advance the company's injectable drug, AA4500, into late-stage trials for Dupuytren's disease, a rare finger-joint condition."
So they canned the CEO for being so slow to get AA4500 on the market? Hmmmmm.
|
|
|
|
|
06/30/2006 23:29
jimh 
|
06/30/2006 23:29
jimh
|
AA4500
The public statement contained the usual line about needing a CEO who could "take the company to the next level" so obviously, things aren't happening and the big investors are unhappy. Gerri Henwood's severance will cost about a half million in cash. A new CEO, Armando Anido, comes in at about $600k plus stock options.
Trials are expected to begin soon.
The years go by, and only the names change.
|
|
|
|
|
07/06/2006 23:17
MysteryMan4Unot registered
|
07/06/2006 23:17
MysteryMan4Unot registered
|
Give them a break
I think people are overly skeptical because of the previous company doing nothing. The company is new and from what I hear the new drug collaganese is making progress. Dr. Levine has reportedly said from some reliable sources, that the drug could be out for peyronies by the end of this year.
|
|
|
|
|
07/06/2006 23:24
jimh
|
07/06/2006 23:24
jimh
|
scoop on collagenase
I hope that happens, but I don't see how it's possible since Phase III trials haven't even begun.
|
|
|
|
|
07/10/2006 23:24
anonnot registered
|
07/10/2006 23:24
anonnot registered
|
scoop on collagenase
Supposedly it has taken a while to get off the ground since the original material used by Biospecifics was created using cow meat media, a non starter these days with BSE fears. So they had to create the drug again using approved techniques and the FDA has had to OK the procedures. Admitedly it has taken longer than they keep saying but drug development isn't a quick process and they sort of had to go back to the drawing board.
|
|
|
|
|
07/18/2006 23:46
jim hnot registered
|
07/18/2006 23:46
jim hnot registered
|
AA4500
What this says to me is that they currently have no supply of AA4500 for Phase III trials so those aren't going to happen anytime "soon". And that they have no source of a commercial supply, and haven't even started discussing the terms of obtaining a commercial supply from Cobra.
Their stock price actually went down 7% on that announcement because it revealed where they're really at with this drug. Check this link:
http://biz.yahoo.com/ap/060717/auxilium_mover.html?.v=1
|
|
|
|
|
08/04/2006 23:38
Stage Onenot registered
|
08/04/2006 23:38
Stage Onenot registered
|
State of the art
Just curious; at what point did anyone notice that something was amiss: 5 degree, 10 degree, 20 degree? etc. Unless a family history exists, I am guessing that most of us were/are concerned about chords and nodules that are
in late stage one or early two. Later stage involvement
has often already been diagnosed. Those individuals are
looking for less invasisve treatment options. I would
be surpised that an early stage one (lacking a family history) would be seeking radiotherapy. Cordase is
not readily available and, I suspect that protocols exclude early stage patients.
Bottomline: I stiil think that NA is the most viable
intervention for known cases of Stage One/Two DD/DC,
if only to buy time for more knowledge/options. Later
stages may involved open surgery; earlier stages are less
likely to have been diagnosed. Perhaps we need to be at
malls with hand outs and table tests. Progress has been made. Thank you Randy H. and others.
|
|
|
|
|
08/27/2006 23:30
Wolfgangnot registered
|
08/27/2006 23:30
Wolfgangnot registered
|
collagenase trial in Switzerland
If people from Switzerland are reading this forum it might be interesting for them that Dr. Georges Rappoport, Lausanne, will participate in phase III of the collagenase trial. Dr. Rappoport is also one of the NA pioneers outside of France.
Due to the frequent and obligatory check-ups that are part of this test, only patients that can easily and repeatedly come into Lausanne should consider participating in this trial. They also need to be aware that they might end up in the dummy group as this is a blind study, if understand it right.
But at least there is progress and collagenase moves into Europe. Good!
The study aims at Dupuytren patients, not at Ledderhose (though it might make a lot of sense there as well).
Wolfgang
|
|
|
|
|
08/27/2006 23:23
jim hnot registered
|
08/27/2006 23:23
jim hnot registered
|
Dr. Rappoport
That's very interesting, as it means that Auxilium is aware of NA and how it compares to treatment by AA4500, and thinks AA4500 would nevertheless have a market.
It doesn't convince me that Auxilium is serious about marketing this product as opposed to just bringing in more investment dollars, but it's a hopeful sign.
|
|
|
|
|
|
1 2 3 4
|
| 1 2 3 4
|
415 users online
Login
